Gilead Sciences Reaches $158.69, Its Second 52-Week High in Two Weeks

As seen on the 24/7 Wall St. homepage on October 26, 2026.

GILD Gilead Sciences
New 52-week high $158.69 +0.8% vs prior high · 2026-10-15
$162$137$113

Gilead Sciences set a new 52-week high at $158.69, clearing its October 15 peak by 0.84% and making this the second record in under two weeks. The $196.8 billion biotech is now roughly a third above where it traded a year ago.

Continue ReadingShow less

Gilead Sciences touched $158.69 on October 26, topping the prior 52-week peak set just on October 15. Back-to-back record highs within a two-week window signal sustained buying pressure.

That roughly one-third gain over twelve months is meaningful for a company of this scale. Gilead carries a market capitalization of $196.8 billion, so the move higher reflects a substantial shift in how the market is pricing the business.

Sponsored

The pace of the recent leg is worth noting. The stock spent much of the spring and early summer consolidating in the $123 to $135 range before accelerating to new highs. A base plus breakout often draws institutional attention.

Investors keeping an eye on the stock will want to see whether it can hold above the October 15 level on any near-term pullback. A failure to do so would mark the latest high as a short-term overshoot.

Mentioned: GILD